ROCO:6733 (Taiwan)
Â
Ordinary Shares
NT$
25.35
-0.35 (-1.33%)
Jul 14
Business Description
BioGend Therapeutics Co Ltd
ISIN : TW0006733009
Share Class Description:
ROCO:6733: Ordinary SharesTotal Employee Number:
27Description
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 78.77 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.12 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 36.69 | |||||
Beneish M-Score | -2.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 80.9 | |||||
3-Year EBITDA Growth Rate | 34.6 | |||||
3-Year EPS without NRI Growth Rate | 27.4 | |||||
3-Year FCF Growth Rate | 33.5 | |||||
3-Year Book Growth Rate | -4.3 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.9 | |||||
9-Day RSI | 57.79 | |||||
14-Day RSI | 53.36 | |||||
3-1 Month Momentum % | -17.85 | |||||
6-1 Month Momentum % | -32.29 | |||||
12-1 Month Momentum % | -14.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 17.6 | |||||
Quick Ratio | 17.03 | |||||
Cash Ratio | 14.32 | |||||
Days Inventory | 103.03 | |||||
Days Sales Outstanding | 87.3 | |||||
Days Payable | 15.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.5 | |||||
Shareholder Yield % | 0.1 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.03 | |||||
Operating Margin % | -49.34 | |||||
Net Margin % | -38.06 | |||||
EBITDA Margin % | -24.15 | |||||
FCF Margin % | -28.63 | |||||
OCF Margin % | -28.63 | |||||
ROE % | -10.93 | |||||
ROA % | -9.88 | |||||
ROIC % | -38.47 | |||||
3-Year ROIIC % | -310.15 | |||||
ROC (Joel Greenblatt) % | -83.66 | |||||
ROCE % | -12.56 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 107.78 | |||||
PS Ratio | 14.87 | |||||
PB Ratio | 4.37 | |||||
Price-to-Tangible-Book | 4.97 | |||||
EV-to-EBIT | -28.97 | |||||
EV-to-EBITDA | -55.81 | |||||
EV-to-Revenue | 13.48 | |||||
EV-to-FCF | -47.81 | |||||
Price-to-GF-Value | 0.37 | |||||
| Price-to-Net-Current-Asset-Value | 5.76 | |||||
| Price-to-Net-Cash | 7.3 | |||||
Earnings Yield (Greenblatt) % | -3.45 | |||||
FCF Yield % | -1.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioGend Therapeutics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 222.337 | ||
| EPS (TTM) (NT$) | -0.687 | ||
| Beta | 0.5851 | ||
| 3-Year Sharpe Ratio | -0.46 | ||
| 3-Year Sortino Ratio | -0.86 | ||
| Volatility % | 66.12 | ||
| 14-Day RSI | 53.36 | ||
| 14-Day ATR (NT$) | 0.807766 | ||
| 20-Day SMA (NT$) | 25.01 | ||
| 12-1 Month Momentum % | -14.57 | ||
| 52-Week Range (NT$) | 23.45 - 48.997305 | ||
| Shares Outstanding (Mil) | 134.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioGend Therapeutics Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioGend Therapeutics Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioGend Therapeutics Co Ltd Frequently Asked Questions
What is BioGend Therapeutics Co Ltd(ROCO:6733)'s stock price today?
The current price of ROCO:6733 is NT$25.35. The 52 week high of ROCO:6733 is NT$49.00 and 52 week low is NT$23.45.
When is next earnings date of BioGend Therapeutics Co Ltd(ROCO:6733)?
The next earnings date of BioGend Therapeutics Co Ltd(ROCO:6733) is .
Does BioGend Therapeutics Co Ltd(ROCO:6733) pay dividends? If so, how much?
BioGend Therapeutics Co Ltd(ROCO:6733) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on BioGend Therapeutics Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers